FDA OKs a trial for a new Covid-19 therapy after an unusual publicity campaign touts its potential — with help from Rudy Giuliani

After taking to the Wall Street Journal to tout the potential of taking their lead natural killer cell therapy and leapfrogging from cancer to Covid-19, while gaining an influential advocate in the White House, Celularity CEO Robert Hariri now has the IND he was looking for from the FDA to start testing this approach in patients.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

FDA OKs a trial for a new Covid-19 therapy after an unusual publicity campaign touts its potential — with help from Rudy Giuliani

To read Endpoints News become a free subscriber

AstraZeneca fleshes out pivotal data on $930M rare blood disorder drug it wants to pair with Soliris, Ultomiris

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

AstraZeneca enlists UK Treg biotech for type 1 diabetes, inflammatory bowel disease deal featuring $85M upfront

Editas gives first look at CRISPR data in sickle cell, beta thalassemia six months after layoffs, refocus

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape

FDA OKs a tri­al for a new Covid-19 ther­a­py af­ter an un­usu­al pub­lic­i­ty cam­paign touts its po­ten­tial — with help from Rudy Giu­liani

To read Endpoints News become a free subscriber

As­traZeneca flesh­es out piv­otal da­ta on $930M rare blood dis­or­der drug it wants to pair with Soliris, Ul­tomiris

Who pays the most (and least) in bio­phar­ma? We crunched me­di­an salary da­ta from 175 com­pa­nies

FDA sets De­cem­ber ap­proval de­ci­sion for first CRISPR ther­a­py, with 94% of pa­tients free of sick­le cell crises

As­traZeneca en­lists UK Treg biotech for type 1 di­a­betes, in­flam­ma­to­ry bow­el dis­ease deal fea­tur­ing $85M up­front

Ed­i­tas gives first look at CRISPR da­ta in sick­le cell, be­ta tha­lassemia six months af­ter lay­offs, re­fo­cus

The new rules of can­cer care: Re­spond­ing to in­creas­ing CMS in­flu­ence on the on­col­o­gy land­scape

FDA OKs a trial for a new Covid-19 therapy after an unusual publicity campaign touts its potential — with help from Rudy Giuliani

AstraZeneca fleshes out pivotal data on $930M rare blood disorder drug it wants to pair with Soliris, Ultomiris

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

AstraZeneca enlists UK Treg biotech for type 1 diabetes, inflammatory bowel disease deal featuring $85M upfront

Editas gives first look at CRISPR data in sickle cell, beta thalassemia six months after layoffs, refocus

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape